
Intravenous 2 is the ultimate blend of tactical gameplay and immersive storytelling. Will you embrace the shadows or confront your foes head-on? The choice is yours. Experience a new era of tactical stealth action. Save lives. Uncover secrets. Take vengeance.
Modeled estimate, not a reported figure. How we estimate →
Prices
Each in the currency that store quoted — not converted: the gap between two rows is the publisher's pricing, not an exchange rate.
Discounts
Every price cut of more than 20% we have observed, in each market that quoted one, with this game's chart position on either side of it. These are episodes, not a model: a sale is one event, and one event cannot tell you what the next one will do.
Reviews, worldwide (the counter carries no country): 2/day in the week to Aug 28 → 3.57/day in the week after.
For scale, across Steam · Top Sellers · Brazil over the last 30 days: the 24 chart moves that followed a price cut of more than 20% went a median of 9 places towards #1, and the 2,404 moves with no price cut behind them went 2 away. One store, one chart, one country — it is the only place we have enough observations to say even that.
Prices outside the United States have been collected since 6 August 2026 and chart positions since 19 July 2026, so a cut older than that has no market to compare and a market that joined later has no history yet. Nothing here is converted between currencies.
About
Genres
Add-ons
Each DLC is estimated with the same model as a game, then summed — a modeled figure, not reported DLC sales.
Sums Steam only; GOG, Xbox publish no volume signal, so the true total is higher by an unknown amount.
| Store | Price | Audience | Score | Chart | Est. revenue |
|---|---|---|---|---|---|
SteamYou are here | $19.99 | 4.1Kreviews | 95% | — | $2.2M |
| $11.99−40% | 62ratings | 90% | — | not modelled | |
Updates
Build ids and update times come straight from Steam's PICS — the same source SteamDB reads. Patch history grows as we record new builds.
Engagement
Reviews
Themes across 218 recent reviews and how positive each mention is. A keyword signal, not full sentiment analysis.
Reviews
Вечная память Владимиру Глебенкову. 10/10, ждём третью часть
The gameplay is absolutely golden
horrible
Media

Related
Related
Price dynamics, follower growth, revenue and sales trajectories with interactive tooltips
This and every other Pro feature is free until October 20, 2026. A free account is all it takes.
Every market we collect.
Stats
All-time low is the lowest price we've recorded for this game since we started tracking it.
Languages: English, French, German, Spanish - Spain, Japanese, Korean, Polish, Russian, Simplified Chinese, Traditional Chinese, Turkish, Portuguese - Brazil +1 more
| Free |
| 0ratings |
| 0% |
| — |
| not modelled |
Matched by title — a reused name can pair the wrong games. * is a critic aggregate. Prices and positions are each store's United States storefront; Epic charts worldwide. Audience and Score too, except Steam's, which is worldwide.
Hours played at review time, across 220 reviews with recorded playtime.
positive critical· bar length = how often the theme comes up
[h1] 不做不错,越做越错 [/h1] 有时候独立游戏作者总是会为了让游戏有特色走了很多前人走过的弯路,静脉注射也不例外。虽然游戏一开始就说了,对耻辱,杀出重围,老细胞分裂(从玩法机制来看尤其是对混沌理论的)玩法参考,但都形似神离。这游戏和我先前玩过的冥河系列类似,自我阉割把潜行和尽量背板路线避开敌人不交互画等号,将无聊粉饰为硬核。 [h1] 你在做一个不鼓励玩家交互的游戏,你绝对是在开玩笑。 [/h1] 游戏ai相比前作更加过分,敌人和敌人会对巡逻路线上有人没来巡逻而警觉,并且还有敌人定期无线电通讯,而且一旦警觉和前作一样是永久性的。也就是说,你每次和敌人交互就是给你后续流程埋潜在的坑,所以玩家唯一方式就是单纯藏好自己,躲开敌人。你难度越高,你的潜行乐趣就会直线下降,从开始感觉貌似有些惊险刺激,到中期就直线下滑成枯燥无味,因为你发现了一个令人失望的事实,你只是不和也不能和任何NPC交互,这在另一方面来说等效于这些NPC不存在,解决敌人却需要背板敌人所有路线才能解决。这不关乎难度的问题,而是这根本就不好玩,其乐趣上来说,静脉注射和很多潜行游戏一样思路在根本上错了,紧张感是各方面设计互相配合才能达到的而非让敌人设计处处针对玩家恶心玩家达到的。这些所谓的难度来自ai的压力,OK没问题,但为了创造压力却用各种方式直接间接削弱玩家的各种自由和策略,导致一个解法单一还强背板的玩法,big No No。 潜行方面的装备构筑也因为敌人设计和拟真设计变得极为单一,因为就算武器有抑制器,它的声音传播和现实一样也有30-50米。一些道具反而会出现反效果比如把不想聚集的敌人都聚集起来,转移敌人注意的道具反而你在多数情况下造成更难处理情形。当然了,如果你受不了游戏非常糟糕的潜行的话,直接选择战斗也不失为一种选择,当然了,如果一半流程杀人了,那坏结局跑不了了。 [h1] flatlander woman [/h1] 由于游戏是2d游戏所以游戏的垂直设计完全为零的同时,有限的存档,糟糕的敌人设计让游戏完全没有让人探索的欲望和容错,尽管相比前作从许多建筑内除了摆设什么都没有,到有了零星的资源和隐藏武器,但还是没有解决根本问题,地图的利用率依然很低,依然有很多地方单纯就是让你忽略的,没有像deus ex那样有环境叙事各种剧情网路。也没有像是1998年的神偷:黑暗计划那样,增加难度并非完全压缩玩家赋权,而是增加更加丰富的任务设计来鼓励玩家在它制作的大型箱庭中寻宝探险,找到更多隐藏区域,发现更多游戏内容。在静脉注射进入各个房间探索地图了除了绕远路,近死路,遇到完全不需要遇到的敌人来增加失败风险以外没什么其他作用,如果游戏能做出像杀出重围、神偷、耻辱那样立体地图多层级的设计倒是能够在这些没用房间增加更多有意义的路线,可惜没有(哈-哈)。 [h1] 形似神离 [/h1] 当我在玩过杀出重围,神偷(当然了还有细胞分裂系列),耻辱后,我对静脉注射2的表现可以说是相当失望,能看出制作者对这些游戏是有一定的参考,但却在这些游戏玩法精髓方面无一例外全部失败了,2d不适合做复杂优秀的关卡设计,潜行游戏不是像冥河系列一样肤浅地放弃交互,不是处处针对玩家。
[url=https://www.youtube.com/watch?v=Azd5DQnYAgI] Hey Hey People[/url], this game is quite peak. Very fun with lot's of freedom. I'm excited For Intravenous 3.
关灯就成战神
Gude Phun/
Good game, took 15 hours to beat the game the first time, another 2 hours to beat it again since this time i went guns blazings rather than just stealth. only complaints are the doors cause ♥♥♥♥♥♥♥ are they finnicky. Also having problems shooting immediately after opening a door causing me to reset many times.
If this is a stealth game, then why would you hide the best soundtrack behind questionable semi-justified mass genocide Mr. John Intravenous (2)?
+İstenmeyen tüy kız ismidir yalnız -Efendim annem hep kız istemiş +Olmamış mı? -Olmuş mu? +Olmamış !
Selling now
See how fast this game is selling right now — estimated copies and revenue per day from recent review growth.
Active players
Estimated daily and monthly active players (DAU/MAU) modeled from peak concurrency.
Players by region
Where this game's players are, estimated from review languages.
Players also reviewed
The games this title's players most often review too — audience affinity.
Related
| Game | Estimated lifetime revenue | Reviews | Review score | Price |
|---|---|---|---|---|
| — | 2.7K | 94% | — | |
| — | 0 | — | — | |
| $0 | 0 | — | Free | |
| $1.1M | 5.6K | 90% | $19.99 | |
| $1.9K | 18 | 100% | $4.99 | |
| $4.6M | 7.9K | 85% | $19.99 |
Related
| Game | Estimated lifetime revenue | Reviews | Review score | Price |
|---|---|---|---|---|
| $2.2M | 4.2K | 97% | $19.99 | |
| $2.2M | 4.6K | 80% | $14.99 | |
| $2.2M | 8.2K | 84% | $14.99 | |
| $2.2M | 6.1K | 83% | $19.99 | |
| $2.2M | 3.1K | 91% | $19.99 | |
| $2.2M | 3.6K | 86% | $29.99 |